Lynk Pharmaceuticals, a pharmaceutical R&D company, has secured $50 million in Series B financing. The investors include Lilly Asia Ventures, New Alliance Capital, Hangzhou HEDA Biological Medicine Venture Capital Partnership, Legend Capital and Med-Fine Capital. CEC Capital was financial advisor to Lynk Pharmaceuticals in this transaction.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: